Author

J. B. Hirdler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

F. Lucien· 2 shared H. Dong· 2 shared J. K. Gicobi· 2 shared M. A. Hsu· 2 shared A. Feven· 1 shared A. S. Mansfield· 1 shared B. C. Leibovich· 1 shared C. Lohse· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

F. Lucien

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Resilient CD8+ T cells maintain a high cytotoxic capacity by balancing ROS via ME1 upregulation

J. K. Gicobi, Z. Mao, G. DeFranco, Y. Li, X. Liu, J. B. Hirdler, V. V. Vianzon, E. R. Dellacecca, M. A. Hsu, W. Barham, Y. H. Kim, A. Feven, W. S. Harmsen, Y. Yan, R. S. Dronca, , H. Dong

This paper identifies CX3CR1+ CD8+ T cells with low mitochondrial membrane potential as functionally resilient, showing high cytotoxicity and reduced ROS through ME1 upregulation, which enhances their anti-tumor activity.

bioRxiv · Nov 25, 2022 · PreprintImmunology

Discovery of a novel monoclonal PD-L1 antibody H1A that promotes T-cell mediated tumor killing activity in renal cell carcinoma

Z. An, M. A. Hsu, J. K. Gicobi, T. Xu, S. M. Harrington, H. Zhang, K. D. Pavelko, J. B. Hirdler, C. Lohse, R. Nabavizadeh, R. R. Pessoa, V. Sharma, R. H. Thompson, B. C. Leibovich, H. Dong, F. Lucien

This study identifies a novel monoclonal PD-L1 antibody H1A that enhances T-cell mediated tumor killing in renal cell carcinoma compared to existing PD-1/PD-L1 inhibitors.

bioRxiv · Sep 10, 2022 · PreprintImmunology